EXACT SCIENCES CORP 4

Paul J. Clancy tendered/converted 26,038 shares of Exact Sciences common stock into $105.00-per-share cash consideration in the Abbott merger, leaving him with no remaining holdings.

On March 23, 2026, in connection with the closing of Abbott Laboratories’ acquisition of Exact Sciences Corporation, all of Paul J. Clancy’s Exact Sciences common shares were converted into cash at the $105.00 per share merger price. A total of 26,038 shares of common stock, including 5,398 previously reported as indirectly or otherwise held, were disposed of in the merger, resulting in Mr. Clancy ceasing to hold any Exact Sciences equity following the transaction. The disposition reflects automatic, transaction-driven conversion of both vested and unvested equity into the cash merger consideration, rather than an open-market sale decision by the insider.

Filing Facts

CIK

1124140

Ticker

EXAS

Form

4

Source Type

sec

Accession

0001193125-26-118743

Alert Tier

6